

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**FORM 8-K/A
(Amendment No. 1)**

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **November 4, 2022**

Aesther Healthcare Acquisition Corp.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

001-40793

(Commission
File Number)

87-1309280

(IRS Employer
Identification No.)

**515 Madison Avenue, 8th Floor – Suite 8078
New York, New York 10022**

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: **(646) 908-2659**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|-------------------|---|
| Units, each consisting of one Class A Ordinary Share and one half of one Redeemable Warrant | AEHAU | The Nasdaq Stock Market LLC |
| Class A Ordinary Share, par value \$0.0001 per share | AEHA | The Nasdaq Stock Market LLC |
| Warrants, each warrant exercisable for one Class A Ordinary Share at an exercise price of \$11.50 | AEHAW | The Nasdaq Stock Market LLC |

Item. 7.01. Regulation FD Disclosure

As announced in a press release and related Current Report on Form 8-K dated August 31, 2022, Aesther Healthcare Acquisition Corp., a Delaware corporation (“Aesther”), entered into an Agreement and Plan of Merger by and among Aesther, Aesther Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Aesther (“Merger Sub”), Aesther Healthcare Sponsor, LLC, Aesther’s sponsor (the “Sponsor”), in its capacity as purchaser representative, Ocean Biomedical, Inc., a Delaware corporation (“Ocean Biomedical”), and Dr. Chirinjeev Kathuria, in his capacity as seller representative (as may be amended and/or restated from time to time, the “Merger Agreement”), pursuant to which, among other things, the parties will effect the merger of Merger Sub with and into Ocean Biomedical, with Ocean Biomedical continuing as the surviving entity (the “Merger”), as a result of which all of the issued and outstanding capital stock of Ocean Biomedical shall be exchanged for shares of Class A common stock, par value \$0.0001 per share, of Aesther (the “Share Exchange”), subject to the conditions set forth in the Merger Agreement, with Ocean Biomedical surviving the Share Exchange as a wholly-owned subsidiary of Aesther (the Share Exchange and the other transactions contemplated by the Merger Agreement, together, the “Transaction”).

On November 1, 2022, Aesther filed a Current Report on Form 8-K (the “Original Filing”) announcing that Aesther posted company presentation materials on its website and Ocean Biomedical posted such company presentation materials on its website (the “Presentation Materials”). The Company is filing this Amendment No. 1 on Form 8-K/A to amend the Original Filing in order to correct an error in the initial version of the Presentation Materials.

A copy of the Presentation Materials is furnished as Exhibit 99.1 to this Amendment No. 1 to Current Report on Form 8-K/A and incorporated into this Item 7.01 by reference. The information contained in, or incorporated into, this Amendment No. 1 to Current Report on Form 8-K/A, including Exhibit 99.1 attached hereto and incorporated by reference into this Item 7.01, are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Furthermore, such information, including the exhibits attached hereto, shall not be deemed incorporated by reference into any of the Company’s reports or filings with the SEC, whether made before or after the date hereof, except as expressly set forth by specific reference in such report or filing. The information in this Amendment No. 1 to Current Report on Form 8-K/A, including the exhibit attached hereto, shall not be deemed an admission as to the materiality of any information in this Amendment No. 1 to Current Report on Form 8-K/A that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Forward-Looking Statements

This filing contains certain statements that are not historical facts and are forward-looking statements within the meaning of the federal securities laws with respect to the proposed Transaction between Aesther and Ocean Biomedical, including without limitation statements regarding the anticipated benefits of the proposed Transaction, the anticipated timing of the proposed Transaction, the implied enterprise value, future financial condition and performance of Ocean Biomedical and the combined company after the closing and expected financial impacts of the proposed Transaction, the satisfaction of closing conditions to the proposed Transaction, the level of redemptions of Aesther’s public stockholders and the products and markets and expected future performance and market opportunities of Ocean Biomedical. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “think,” “strategy,” “future,” “opportunity,” “potential,” “plan,” “seeks,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: (i) the risk that the proposed Transaction may not be completed in a timely manner or at all, which may adversely affect the price of Aesther's securities; (ii) the risk that the proposed Transaction may not be completed by Aesther's business combination deadline; (iii) the failure to satisfy the conditions to the consummation of the proposed Transaction, including the approval of the Merger Agreement by the stockholders of Aesther, the satisfaction of the minimum net tangible assets and minimum cash at closing requirements and the receipt of certain governmental, regulatory and third party approvals; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (v) the failure to achieve the minimum amount of cash available following any redemptions by Aesther's stockholders; (vi) redemptions exceeding anticipated levels or the failure to meet The Nasdaq Global Market's initial listing standards in connection with the consummation of the proposed Transaction; (vii) the effect of the announcement or pendency of the proposed Transaction on Ocean Biomedical's business relationships, operating results, and business generally; (viii) risks that the proposed Transaction disrupts current plans and operations of Ocean Biomedical; (ix) the outcome of any legal proceedings that may be instituted against Ocean Biomedical or against Aesther related to the Merger Agreement or the proposed Transaction; (x) changes in the markets in which Ocean Biomedical competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; (xi) changes in domestic and global general economic conditions; (xii) risk that Ocean Biomedical may not be able to execute its growth strategies; (xiii) risks related to the ongoing COVID-19 pandemic and response, including supply chain disruptions; (xiv) risk that Ocean Biomedical may not be able to develop and maintain effective internal controls; (xv) costs related to the proposed Transaction and the failure to realize anticipated benefits of the proposed Transaction or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions; (xvi) the ability to recognize the anticipated benefits of the proposed Transaction and to achieve its commercialization and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Ocean Biomedical to grow and manage growth economically and hire and retain key employees; (xvii) the risk that Ocean Biomedical may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; (xviii) the ability to develop, license or acquire new therapeutics; (xix) the risk that Ocean Biomedical will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (xx) the risk that Ocean Biomedical, post-combination, experiences difficulties in managing its growth and expanding operations; (xxi) the risk of product liability or regulatory lawsuits or proceedings relating to Ocean Biomedical's business; (xxii) the risk of cyber security or foreign exchange losses; (xxiii) the risk that Ocean Biomedical is unable to secure or protect its intellectual property; and (xxiv) those factors discussed in Aesther's filings with the SEC and that are contained in the preliminary proxy statement relating to the proposed Transaction and will be contained in the definitive proxy statement relating to the proposed Transaction.

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that are described in Aesther's Annual Report on Form 10-K for the year ended December 31, 2021, and which are described in the "Risk Factors" section of the preliminary proxy statement and the amendments thereto, and will be described in the "Risk Factors" section of the definitive proxy statement, and other documents to be filed by Aesther from time to time with the SEC and which are and will be available at www.sec.gov. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and while Ocean Biomedical and Aesther may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Neither Ocean Biomedical nor Aesther gives any assurance that Ocean Biomedical or Aesther, or the combined company, will achieve its expectations. These forward-looking statements should not be relied upon as representing Aesther's or Ocean Biomedical's assessments as of any date subsequent to the date of this filing. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Additional Information and Where to Find It

In connection with the Merger Agreement and the proposed transaction, Aesther has filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy statement on Schedule 14A relating to the proposed transaction. This communication is not intended to be, and is not, a substitute for the preliminary proxy statement or any other document that Aesther has filed or may file with the SEC in connection with the proposed transaction. Aesther’s stockholders and other interested persons are advised to read the preliminary proxy statement and the amendments thereto, and, when available, the definitive proxy statement and documents incorporated by reference therein filed in connection with the proposed transaction, as these materials will contain important information about Aesther, Ocean Biomedical, the Merger Agreement, and the proposed transaction. When available, the definitive proxy statement and other relevant materials for the proposed transaction will be mailed to stockholders of Aesther as of a record date to be established for voting on the proposed transaction. Before making any voting or investment decision, investors and stockholders of Aesther are urged to carefully read the entire preliminary proxy statement and definitive proxy statement, when it becomes available, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, because they will contain important information about the proposed Transaction. Aesther investors and stockholders will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement, and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to: Aesther Healthcare Acquisition Corp., 515 Madison Avenue, Suite 8078, New York, NY 10022, Attention: Mr. Suren Ajjarapu.

Participants in the Solicitation

Aesther, Ocean Biomedical and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Aesther’s stockholders with respect to the proposed transaction. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed transaction of Aesther’s directors and officers in Aesther’s filings with the SEC, including its most recent Annual Report on Form 10-K, the preliminary proxy statement and the amendments thereto, and when filed with the SEC, the definitive proxy statement, and other documents filed with the SEC. Such information with respect to Ocean Biomedical’s directors and executive officers is also included in the preliminary proxy statement and will be included in the definitive proxy statement.

No Offer or Solicitation

This filing is not a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction and will not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

| Exhibit No. | Description |
|--------------------|---|
| 99.1 | Presentation materials dated November 4, 2022 |
| 104 | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit) |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Aesther Healthcare Acquisition Corp.

Dated: November 4, 2022

By: /s/ Suren Ajarapu
Suren Ajarapu
Chief Executive Officer



Ocean Biomedical Company Overview

November 2022

Empowering Great Science. **Accelerating** Translation. **Changing** Medicine.

Disclaimer

This presentation, prepared by Ocean Biomedical, Inc. ("Ocean" or the "Company"), is solely for informational purposes and is strictly confidential. The forwarding of such information to third parties is prohibited unless Ocean Biomedical has granted express permission to do so.

This presentation contains estimates and other information concerning Ocean Biomedical's industry that are based on third party reports. This information involves a number of assumptions and limitations, and Ocean Biomedical has not independently verified the accuracy or completeness of the information.

The Company has filed a registration statement (including a preliminary prospectus) on Form S-1 with the Securities and Exchange Commission (the "SEC") related to a planned public offering of its shares. The registration statement has not yet become effective. This presentation is not an offer to sell any securities of the Company, and the Company may not sell any securities, nor can it accept offers to buy any securities, prior to the time the registration statement becomes effective. Before even considering an investment, any prospective investor should read the preliminary prospectus in that registration statement and the other documents the Company has filed with the SEC for more complete information about the Company and its proposed public offering. These documents can be obtained for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the preliminary prospectus may be obtained from Roth Capital Partners or from Jones Trading.

Certain statements contained in this document that are not historical facts may be considered forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "ambitioned," "should" and "will" and similar expressions as they relate to Ocean Biomedical including its subsidiaries are intended to identify such forward-looking statements. Neither Ocean Biomedical nor any advisor of Ocean Biomedical undertakes any obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that may cause actual results to differ materially from expectations. Ocean Biomedical is providing this information as of the date of this presentation and does not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise. Readers are advised not to rely unduly on these forward-looking statements, which refer only to the relevant dates.

No warranty of any kind, implied, expressed or statutory, is given in conjunction with the information set forth herein. The Company makes no representations or warranties, express or implied, as to the accuracy or completeness of any information, statements and estimates presented herein. Neither the SEC nor the Securities Regulatory Authority of any state, foreign or other jurisdiction has passed upon the accuracy or adequacy of this presentation.

Under no circumstances may a copy, in any format, be shown, reproduced, transmitted, or otherwise provided to any person other than the authorized recipients. By accepting this Presentation, the recipient acknowledges that the Company considers this Presentation and all information contained herein to include confidential, sensitive and proprietary information and agrees that it shall use reasonable precautions to keep this Presentation and all information contained herein confidential and shall not use any such information for any purpose other than to consider its potential interest in investing in the Company in the future and for no other purpose.

About Aesther Healthcare Acquisition Corp.

About Aesther Healthcare Acquisition Corp.

Purpose

- Aesther Healthcare is a serial special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses

Focus

- Public/private market investing experience and operational knowledge to bring real added value benefits to the target, including strong access to transformative technologies
- Ability to step into management roles and/or operational support, if needed

Experienced Team

- Team with a diverse background able to source, evaluate and transact with potential targets
- Substantial experience investing in as well as operating businesses in multiple sectors
- Significant long-term track record in creatively structuring transactions to unlock and maximize value

Management Team



Suren Ajarapu

Chairman and Chief Executive Officer

- 25+ years of experience in growing novel technology-based companies
- CEO of TRxADE Health, Inc. (Nasdaq: MEDS)
- Director of OceanTech Acquisitions I Corp. (Nasdaq: OTECU)



Howard Doss

Chief Financial Officer

- Long career as a financial executive and accountant
- Previously CFO of TRxADE Health, Inc. (Nasdaq: MEDS)
- Previously CFO of Sansur Renewable Energy




Transaction Overview

Key Transaction Highlights

- Aesther Healthcare Acquisition Corp. ("AEHA") has agreed to acquire Ocean Biomedical, Inc. ("OCEA") at a purchase price of approximately \$240M
- The proposed transaction structure includes access to backstops totaling up to approximately \$77M
- AEHA and OCEA can additionally access up to \$75M through a common stock purchase agreement announced Sept. 8, 2022
- Expected transaction close is Q4 2022

Pro Forma Ownership⁽¹⁾



Illustrative Sources & Uses

| Sources | |
|--------------------------------------|----------------------|
| AEHA Cash in Trust ⁽²⁾ | \$26,775,000 |
| OCEA Rollover Equity | 240,000,000 |
| Total | \$266,775,000 |
| Uses | |
| Cash to Balance Sheet ⁽³⁾ | \$18,625,000 |
| OCEA Rollover Equity | 240,000,000 |
| Transaction Expenses ⁽⁴⁾ | 8,150,000 |
| Total | \$266,775,000 |

Valuation Summary

| | |
|---|----------------------|
| Implied Pro Forma Equity Value | \$293,500,000 |
| Plus: Net Debt ⁽³⁾ | (18,625,000) |
| Implied Pro Forma Enterprise Value | \$274,875,000 |

⁽¹⁾ Pro Forma ownership on a non-fully diluted basis at \$10.00/share

⁽²⁾ AEHA Cash In Trust assumes 75% redemptions by AEHA shareholders

⁽³⁾ Cash to Balance Sheet (Net Debt) assumes \$26.8M AEHA Cash in Trust less \$8.2M Transaction Expenses

⁽⁴⁾ Transaction Expenses include Deferred IPO Underwriting Fee and an estimated \$5.0M in Other Transaction Expenses



Ocean Biomedical unlocks inventions from top research institutions to continually fuel its growth engine

1

Innovative business model bridges the 'bench-to-bedside' gap by accelerating the commercialization of innovative assets contained within research universities and medical centers

2

Initial core portfolio in oncology, fibrosis, and infectious disease, all based on new target discoveries enabling first-in-class drug and vaccine candidates - developed through past and on-going grants totaling \$123.9 million

3

Experienced management team has demonstrated scientific, clinical and commercial expertise at the highest levels of the biopharma industry

4

Diversified pipeline with multiple shots-on-goal across varying indications - built from relationships with leading research institutions

5

Potential to leverage our core portfolio into adjacent diseases with similar biological pathways - plus existing and new relationships with research institutions

Management team and advisors with deep experience in drug development, pharma strategy, innovation management, and breakthrough science



Elizabeth Ng
CEO, Director

Proven biotechnology strategic leader
Bioelectric Devices, BioMarin
Pharmaceutical, Merck & Co, Gilead
Sciences, Strategic Decisions Group
MBA Stanford, BS Massachusetts Institute
of Technology



Dr. Chirinjeev Kathuria
Co-Founder, Executive Chair

Entrepreneur and Inventor
UpHealth, New Generation Power Intl., Mircorp,
Nighthawk Radiology Holdings, X-Stream
Networks
MBA Stanford, BS and MD Brown University



Dr. Jack A. Elias
Co-Founder, Chair of SAB

Dean of Medicine, Brown University
Chief of Pulmonary & Critical Care, and Chairman
of the Department of Medicine, Yale University
Member, National Academy of Medicine, past
President, American Association of Physicians
MD and BA University of Pennsylvania



Gurinder Kalra
CFO

Finance leader with a proven track
record
Morgan Stanley, Bear Stearns, Crosslink
LLC
MBA Harvard, BS / BA Brown University



Dr. Jonathan Kurtis
Co-Founder, Director

Internationally recognized expert in infectious
disease; Director, Center for International Health
Research
Chair, Dept. of Pathology and Lab Medicine, and
Director, MD/PhD program, Brown University
MD, PhD, and BS Brown University



Daniel Behr
EVP of Academic Partnerships

Entrepreneur, venture investor, tech transfer
expert
Rediscovery Life Sciences, Access BridgeGap
Ventures, Brown, Harvard, Bain & Co.
MBA Harvard, BS Georgia Institute of
Technology



Independent directors and advisors bring a wealth of experiences in corporate governance, science, and clinical development

Independent Directors



Martin Angle

Deputy Chairman and Senior Independent Director of Spire Healthcare and Gulf Keystone Petroleum, Executive career at S.G. Warburg & Co, Morgan Stanley, Dresdner Kleinwort, TI Group plc, Terra Firma Capital Partners
B. Sc. University of Warwick



Dr. Michelle Berrey

President R&D and CMO, Intercept; past President, CEO, & CMO, Chimerix, and CMO, Pharmasset Inc (GSK); Director at Planned Parenthood Federation of America; SAB at Viiv/GSK; NC Biotech Center Board Sr. Fellow, ID Medicine, U. of Washington
M.D. College of Georgia, M.P.H., B.A. Emory University



Governor Bill Owens

Director & Chair of Corp. Gov. Committee, Federal Signal Corp.; Board Chair, Credit Bank of Moscow
Former Director at High Point Resources Corp, Key Energy Services, Cloud Peak Energy.
Governor of Colorado, from 1999-2007
M.P.A. University of Texas, B.S. Austin State University



Jerome Ringo

Goodwill Ambassador, Trade and Investment, Pan-African Parliament
Founder and Chairman of Zoetic Global (breakthrough energy technologies for African developing nations)
Director, Environmental Defense Fund 2018-2020
Led National Wildlife Federation and Apollo Alliance

Scientific Advisory Board



Dr. Wafik El-Deiry

Discovered a p53 target gene kinase inhibitor that bears his name: WAF1
Associate Dean for Oncologic Sciences, Brown Medical School
Medical Oncologist, RI Hospital
M.D. and Ph.D. University of Miami



Dr. Erol Fikrig

Developer of the first vaccine against Lyme disease
Section Chief for Infectious Diseases, Yale University School of Medicine
Howard Hughes Medical Institute investigator
M.D. Cornell



Dr. Roy Herbst

Nationally recognized leader in lung cancer
Chief of Medical Oncology, Yale Cancer Center
Chief of Thoracic Medical Oncology, M.D. Anderson Cancer Center
M.D. Cornell, Ph.D. Rockefeller University; fellowship at Dana Farber Cancer Institute



Dr. William H. Koster

SVP Drug Discovery, Bristol Myers Squibb
CEO and Director, Neurogen Corp
Chairman, eXithera, OcuTerra; Director Cadus, Cadent, Elicio
Ph.D. Tufts University

Drug Development Advisors



Jackie Ernst - Drug Development

Leader in commercial development and branding of pharmaceuticals
PPD (now Thermo Fisher Scientific, GSK, Ciba-Geigy Pharmaceuticals)
MBA Stanford, B.S. University of Virginia



Dr. Jane Halpern - Regulatory

Leader of pharmaceutical regulatory affairs in government and industry
NIAID, NIH, Novavax, Genocera, Glaxosmithkline, ID Biomedical Corp
PhD University of Rochester, B.S. UC Davis



Dr. Jeff Tepper - Preclinical Safety

Entrepreneur, consultant, expert in drug safety
Teppertox Nonclinical Consulting, Catalyst Biosciences, Aerovance, Bayer, Genentech
PhD and MS University of Rochester, B.S. University of Maryland

Ocean Biomedical is not 1 company but rather 3 companies in one - plus our business model ensures continual growth

OCEAN BIOMEDICAL


Parent Operating Company

- Sub co. oversight
- Operational efficiency
- Nimble drug development

| | Competitive Advantages* | Current Indications & Drug Candidates* | Growth Potential* |
|-----------------------------------|---|---|--|
| Oncology Sub Co. | <ul style="list-style-type: none"> • Novel biological targets with strong and broad patent positions • Targets are 'master-switches' of disease and thus likely to work for broader patient populations | <ul style="list-style-type: none"> • NSLC - mAb • NSLC - bi-specific • GBM - bi-specific | Additional lung cancer indications plus other visceral cancers (liver, breast, kidney, pancreas) |
| Fibrosis Sub Co. | | <ul style="list-style-type: none"> • IPF - small mol. • HBS - small mol. | Other fibrotic diseases (scleroderma, NASH, alcoholic liver disease) |
| Infectious Disease Sub Co. | | <ul style="list-style-type: none"> • Malaria - vaccines • Malaria - mAb | Other infectious diseases (TB, the next pandemic virus, etc.) |

PLUS: Continual growth via new subsidiary companies based on new programs acquired from existing and new relationships with universities, medical centers, and their researchers with whom Ocean is positioned as the 'partner of choice'

Opportunity: bridge the 'bench-to-bedside' gap by turning biomedical inventions from research institutions into products for unmet needs



26,000/year invention disclosures*
\$71B/year research expenditures*
Few cross the gap and reach the market *

Patients with unmet medical needs
Pharma companies with dry pipelines

**Driven by the goal of getting drugs to patients;
Working with leading experts to accelerate the development of innovative
therapeutics and provide new models for academic partnerships**

Our business model and strategy are designed to benefit patients and efficiently create value for our stakeholders and partners

Access to innovations from research universities and medical centers...

- Equity in program subsidiaries* (10% to inventors, 10% to institution)
- Participation in ongoing development

Value Advantage:

- Continuous flow of inventions & technologies to fuel our growth

OCEAN BIOMEDICAL

Parent Operating Company

(to be publicly listed - NASDAQ:OCEA)

Portfolio oversight and operational efficiency for enhanced candidate development

Wholly Owned Subsidiary Companies



Portfolio diversification to optimize value creation and to mitigate risk




Optimized commercialization pathways...

- Internal development all the way to market
- Spin-outs / IPOs
- Partnerships with biopharma

Value Advantage:

- Maximize patient benefit and economic value

Approach: designed to make Ocean the 'partner of choice' for universities, medical centers and their researchers

| Typical Options for Institutions/ Researchers | | Challenges | Ocean Differentiation |
|---|------------------------------|--|---|
|  | License to pharma | <ul style="list-style-type: none"> Pharma prefers later-stage assets Economic upside is limited Upside only if ultimate product is based on licensed IP (It often is not) | <ul style="list-style-type: none"> Development-stage agnostic Inventors and their institutions get equity upside via 20% share* Inventors get to stay involved |
|  | Launch a startup | <ul style="list-style-type: none"> Requires a dedicated team Raising funds is difficult Progressive dilution erodes economics Time consuming | <ul style="list-style-type: none"> Avoid hassles of starting a company Less dilution Fast |
|  | Incubate / Accelerate | <ul style="list-style-type: none"> Available at only a few institutions Often academically focused and will not advance commercial readiness Slow | <ul style="list-style-type: none"> Appropriately scaled Commercially minded Designed for Efficiency |

* Applies to designated future subsidiaries dedicated to specific programs to be in-licensed.

Ocean's initial portfolio addresses high-value and high-impact indications

Our main programs in oncology, fibrosis, and infectious diseases are *all nearing IND application*, are licensed from Brown University and RI Hospital, and have been developed through past and on-going grants totaling \$123.9M.



Oncology

Chi3L1
(Chitinase-3-Like 1)

Innovation:

New master-switch biological target for most visceral cancers

Humanized monoclonal and bi-specific antibodies with promising activity

Lead Indications:

NSCLC (non-small cell lung cancer) - still a major unmet need

GBM (glioblastoma multiforme, commonly known as brain cancer) - no cure available



Fibrosis

Chi1
(Chitinase 1)

Innovation:

Novel target related to that in oncology

A **well-tolerated small molecule** shows promising potential against multiple fibrotic diseases

Lead Indications:

IPF (idiopathic pulmonary fibrosis) - current treatments are sub-optimal

HPS (Hermansky-Pudlak syndrome - a rare orphan disease) - no approved drugs



Infectious Diseases

PfGARP,
PfSEA-1

Innovation:

New targets identified via proprietary discovery platform (**'Whole-Proteome Differential Screening'**)

Malaria **vaccine & therapeutics** with potential for robust clinical activity

Lead Indication:

Malaria affects billions of people, is the single biggest killer of children under 5 - current treatments are sub-optimal (including the recently hyped Mosquirix) or losing the battle to resistance.

Ocean's current pipeline presents multiple 'shots on goal'

Pipeline leverages research university/medical center partnerships to bring diverse and innovative candidates through preclinical studies

| | Franchise | Candidate | Drug Type | Biological Targets | Indication | Estimated Patient Population | IND Filing Target | Pre-IND | IND Enabling | IND Filed | Phase 1 | Phase 2 | Phase 3 | |
|---|--------------------|-----------|----------------|--------------------|---------------------|--|-------------------|---------|--------------|-----------|---------|---------|---------|--|
| Innovations from Brown University and RI Hospital | Oncology | OCX-253 | mAb | Chi311 | NSCLC | 460K US 595K EU5 | H2'23 | | | | | | | |
| | | OCX-410 | Bispecific mAb | Chi311+PD-1 | NSCLC | | H2'23 | | | | | | | |
| | | OCX-909 | Bispecific mAb | Chi311+CTLA-4 | GBM | 28K US | H1'24 | | | | | | | |
| | Fibrosis | OCF-203 | Small Molecule | Chit1 | IPF | 160K US 64K EU | H2'23 | | | | | | | |
| | | | | | HPS | 1.8K U.S. | H2'23 | | | | | | | |
| | Infectious Disease | ODA-570 | Vaccine | PFSEA-1 & PFGARP | Malaria Prophylaxis | 3.4B at risk WW 200M infected WW149M travel WW | H2'23 | | | | | | | |
| | | ODA-611 | mAb | PFGARP | Malaria Therapeutic | 200M WW | H1'24 | | | | | | | |
| | | ODA-579 | Small Molecule | | | | H1'24 | | | | | | | |

Ocean has core expertise/capabilities and leverages external resources

OCEAN BIOMEDICAL

Core operating team skilled at selecting assets and driving them through development

+

External capabilities & capacity to accelerate development of multiple programs



Drug Development Advisors

Jackie Ernst
Drug Development
PPD **gsk**

Dr. Jeff Tepper
Preclinical Safety
BAYER **Genentech**

Dr. Jane Halpern
Regulatory
NIH **NOVAVAX**

Execution Advisory Services

AliraHealth

Joint Ventures


TBD

CROs / CMOs


LONZA

WuXi AppTec

We use a disciplined criteria-driven process to identify, assess and select new programs and indications - and to continually review existing ones



IPOs and private financings reflect strong market interest in programs comparable to Ocean's*



* Comparable companies or transactions, particularly for publicly traded businesses, are not necessarily dispositive of the valuation or prospects of Ocean Biomedical, Inc., which is a private enterprise. Other differentiating factors between such companies or transactions and Ocean Biomedical, Inc. may include stage of development of product candidates, narrowness or diversification or targeted indications, capitalization, management and business prospects.

¹ Market cap figures as reported by NASDAQ at the close of trading on 10/4/22

Ocean's valuation is extremely attractive vs. our peer group, particularly considering that Ocean is the parent company of 3 biotech companies



* Market cap as reported by NASDAQ (or NYSE in the case of Nuvant) at the close of trading on 10/4/22

M&A transactions in IPF and oncology highlight Ocean's potential for exceptional value creation

| IPF | Transaction | Clinical Stage (at Transaction) | Valuation at Transaction | PTRS-Adjusted Implied Valuation ¹ |
|-----|--------------------------|---------------------------------|--------------------------|--|
| | Roche - Intermune, 2014* | Ph III | \$8.3B ^R | \$8.3B |
| | Biogen - Stromedix, 2012 | Ph II | \$563M ^R | \$3.3B |
| | Samumed - United, 2018 | Ph I | \$350M ^P | \$2.5B |
| | Roche - Promedior, 2019 | Ph II | \$1.4B ^R | \$8.2B |

*Now in the market as Roche's Esbriet - \$1B in 2021⁴. The only other approved IPF drug is Boehringer Ingelheim's Ofev - \$2.6B in 2021⁵

There is still a need for effective IPF therapies given the side effect profiles of currently available products

| Oncology (Kinase Inhibitors) | Transaction | Clinical Stage (at Transaction) | Valuation at Transaction | PTRS-Adjusted Implied Valuation ² |
|------------------------------|-----------------------------------|---------------------------------|--------------------------|--|
| | Lilly - Loxo, 2019 | Approved | \$8.0B ^R | \$8.0B |
| | Celgene - Avila, 2012 | Ph I | \$925M ^C | \$7.7B |
| | Lilly - AurKa, 2018 | Ph I | \$575M ^P | \$4.8B |
| | Roche - Ignyta, 2017 ³ | Ph II | \$1.7B ^R | \$8.5B |

Oncology remains a hot-bed of M&A activity.

Five-year survival rates for lung cancer lag well behind other cancers, and the disease exacts a significant burden on society

There is still a dire need for effective NSCLC treatments






¹Using KPMG IPF small molecule PTRS figures
²Using DIMasi average clinical phase transition figures
³Includes NSCLC target
^RReuters
^PPR Newswire
^CCelgene - ir.celgene.com

⁴Roche 2021 Annual Report
⁵Boehringer Ingelheim 2021 Annual Report

Ocean is positioned to deliver outsized returns for our shareholders

- Our valuation is extremely attractive compared to our peer group – especially considering that Ocean is the parent company of 3 biotech companies (oncology, fibrosis, infectious diseases).
- Ocean Biomedical does not have legacy preferred shareholders who often over-inflate valuations.
- Ocean’s multi-asset platform strategy significantly improves our rate of success vs single-platform companies and provides a continuous stream of value inflection points.
- Our business model is an engine for continual growth through preferred access to best-of-breed biomedical innovations from universities and medical research centers.
- Ocean’s optionality in selecting favorable commercialization pathways ensures maximum value-capture.


The success of similar 'portfolio R&D' approaches supports the potential of Ocean's business model*

| Comparable Example | Approach ¹ | Ocean Business Model Differentiation |
|---|---|---|
|  | <ul style="list-style-type: none"> • Founded 2015 • Focused primarily on single-gene rare diseases • "Creates a bridge from remarkable advancements in genetic science to patients with unmet needs" • Decentralized subsidiary model, shared central resources | <ul style="list-style-type: none"> • More broadly diversified portfolio • Not just rare disease focused • More attractive terms for researcher partners • Leadership team with experience in industry, startups, venture capital, and tech transfer |
|  | <ul style="list-style-type: none"> • Founded by MPM Capital 2016 • Oncology focus • "Develop a portfolio of highly promising 'one-off' assets" • Efficiency in shared services | |
|    | <ul style="list-style-type: none"> • Purpose: develop select assets from partner institutions up to a certain stage (IND-enabling or IND submission) • Bridge Medicines: Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine • Blavatnik Biomedical Accelerator: Harvard • Blavatnik Fund for Innovation: Yale | <ul style="list-style-type: none"> • Appropriately scaled and structured to take assets beyond IND • More attractive terms for individual researchers • Partnerships not limited to particular institutions |

* Comparable companies or transactions, particularly for publicly traded businesses, are not necessarily dispositive of the valuation or prospects of Ocean Biomedical, Inc., which is a private enterprise. Other differentiating factors between such companies or transactions and Ocean Biomedical, Inc. may include stage of development of product candidates, narrowness or diversification or targeted indications, capitalization, management and business prospects.

¹ Based on information published in each comparable entity's website

Sustainable growth strategy is opportunistic with regards to indications, diseases, and therapeutic areas





Oncology (NSCLC, GBM)

Non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM) have significant unmet needs



Non-small cell lung cancer (NSCLC)

Leading cause of cancer death and second most diagnosed cancer in the US

- Affects approximately 460,000 people in the U.S.
- Accounts for about 85% of new lung cancers
- Early Diagnosis is essential as 40-50% of patients are diagnosed with Stage IV disease
- NSCLC continues to rank among the cancers with the lowest 5-year survival rates

Current treatments not curative

- Primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly
- Targeted agents and the PD1s have revolutionized treatment, but most patients will still progress, needing new options



Glioblastoma multiforme (GBM)

Lethal type of brain tumor with a single-digit 5-year survival rate

- Affects approximately 28,000 people in the U.S.
- Median survival rate is ~15 months, and 5-year survival is just 8% for those aged 45-54 and 5% for those aged 55-64
- ~25% of GBM patients are not actively treated due to rapid disease progression

Very limited treatment options and no cure

- Treatment usually involves surgery, followed by chemotherapy and radiation
- Very limited treatment options for second-line therapy
- No curative therapies exist for the disease and there have been multiple pipeline failures

Anti-Chi3L1 humanized mAbs are inhibitors of primary and metastatic lung cancer and brain cancer in murine models

Science

Chitinase 3-like-1 (Chi3L1)

Novel target & pathway discovery:

- Dysregulated and plays a critical role in the pathogenesis of primary and metastatic lung cancer.
- Plays a synergistic effect with checkpoint inhibitors such as PD1

Ocean's Innovation



Neutralizing antibodies against Chi3L1 have been developed that are:

- Highly avid
- Specific
- React with mouse, human and monkey Chi3L1 moieties
- Effectively expressed and humanized

Bi-specific antibodies have been developed that target Chi3L1 and PD1

These antibodies have shown promise in animal models as a **treatment of primary and metastatic lung cancer and brain cancer** - as mono-therapies, in combination with checkpoint inhibitors, or in bi-specific modality

Data and Results



Key takeaways about our humanized monoclonal antibody (mAb) therapeutic candidates in oncology

Scientifically Compelling

- **Novel target:** chi3l1 is a master regulator of many visceral tumors regardless of genetic mutations
- **First-in-class:** proprietary mono-specific and bispecific mAbs are first to target chi3l1
- **Efficacy proof of concept:** 85-95% reduction in primary and metastatic tumor burden in multiple animal models
- **Safety data:** no adverse effects in animal models (10mg/kg); chi3l1 knock-out model shows no phenotype; mAbs are generally well-tolerated in humans given their inherent target specificity
- **Chi3L1 is also an excellent biomarker:** serum levels predict severity and prognosis in multiple tumor types

Commercial potential

- **Seeks to address major unmet need** in initial indications for lung and brain cancers
- **Synergistic with other therapeutics:** multiplicative activity shown with immune checkpoint inhibitors in animal models


Opportunity for growth into adjacent cancer indications

- **Potential for expansion to other visceral cancers:** beyond lung and brain to breast, liver, colon and others



Fibrosis (IPF, HPS)

Fibrosis affects most organs and tissues and is a leading cause of morbidity and mortality



Idiopathic pulmonary fibrosis (IPF) & Hermansky-Pudlak Syndrome (HPS) have significant unmet needs



Idiopathic pulmonary fibrosis (IPF)

Progressive disease that results in irreversible loss of lung function with high morbidity and mortality rates

- IPF prevalence in the US has been reported to range from 10 to 60 cases per 100,000, while in Europe it ranges from 1.3 to 32.5 cases per 100,000
- Prevalence is much higher in patients >50 and is also higher in males

No disease modifying agents; standard-of-care only slows decline in lung function

- No disease modifying agents available
- Standard-of-care (SoC) therapeutics have significant side-effects, and a high proportion of patients chose not to take the drug therapy



Hermansky-Pudlak Syndrome (HPS)

Rare, genetic, disease with highest prevalence occurring in Puerto Rico (1 case per 1,800)

- HPS related pulmonary fibrosis occurs early in life (30's-40's) and has a 10-12 year mean survival rate
- Symptoms are severe including highly penetrable pulmonary fibrosis, oculocutaneous albinism (OCA), bleeding due to platelet dysfunction and colitis in some groups of young adults.

No approved therapeutics for HPS related pulmonary fibrosis

- Patients often resort to off-label use of IPF SoC, which has poor side-effects
- Few HPS interventional clinical trials

OCF-203 inhibits Chitinase 1 (Chit1) and demonstrates anti-fibrotic properties in murine models

Science

Chitinase 1 (Chit1)

Novel target & pathway discovery:

Key regulator of tissue damage and remodeling.

- Critical biomarker and therapeutic target in SSc-ILD (Scleroderma-associated interstitial lung disease)
- Plays role in bleomycin- and IL-13 induced pulmonary fibrosis
- Expressed in an exaggerated manner in IPF where it correlates inversely with Smad 7
- Augments TGF- β 1-stimulated receptor expression and canonical Smad 2/3 signaling. The TGF- β 1 stimulating effects of Chit 1 are mediated by its ability to decrease the expression of Smad 7 which inhibits canonical TGF- β 1 signaling and tissue responses



Ocean's Innovation

OCF-203 (Small Molecule X, or SMX) was identified via high throughput screening as a promising Chit 1 inhibitor with potent anti-fibrotic effects in murine models.

- Is a water-soluble antibiotic - but with poor antibiotic performance

OCF-203 has been evaluated in multiple models of pulmonary fibrosis with **impressive reductions in fibrosis** including the Hermansky-Pudlak 'pale ear' mouse model

Data and Results



Key takeaways about our small molecule therapeutic candidate in fibrosis

Scientifically Compelling

- **Novel target:** chit1 is key regulator of tissue damage and remodeling
- **Potential for disease-modifying activity:** 85-90% reduction in collagen accumulation in 4 pulmonary fibrosis animal models
- **Well-tolerated** based on previous clinical Ph 1 studies and EPA data

Strong commercial potential

- **Seeks to address a major unmet need:** current IPF drugs are not disease modifying and have severe side effects
- **Potential for accelerated development and market access** for HPS through the Orphan Drug Designation regulatory pathway

Opportunity for growth into adjacent fibrotic diseases

- **Potential expansion beyond IPF and HPS:** for example to scleroderma, alcoholic liver disease and NASH



Infectious Diseases (Malaria)

Malaria is a deadly disease with significant unmet therapeutic needs

~3 billion

At risk of infection annually worldwide

200-300 million

Infected annually worldwide

500,000+

Children under age 5 killed annually



The Need:

Massive unmet public health need with **no effective prophylactic vaccine**

Despite the recent hype and a \$1B grant from Gates, **Mosquirix has serious side effects and shows limited effectiveness**


SoC therapeutics have **potential risk from drug resistant strains** of malaria, posing future risk to global health and the therapeutics treatment landscape

Large traveler and military populations in endemic regions at risk of malaria - continued compliance issues with current prophylactics

The discovery of PfSEA-1 and PfGARP enables a promising new strategy for combating malaria which kills 500,000 children per year

Science

Malaria - Life-threatening disease



Caused by parasites and transmitted through the bites of infected female Anopheles mosquitoes. Five parasite species cause malaria in humans, the deadliest of which is *Plasmodium falciparum* (*P. falciparum*).



Malaria caused by ***Plasmodium falciparum*** remains the leading single-agent killer of children. **GSK's Mosquirix has limited efficacy and significant safety concerns** (it targets the sporozoites phase). Despite \$1B from the Gates Foundation and a recommendation by the WHO, it is reputedly not more effective than mosquito netting.

Ocean's Innovation

Whole Proteome Differential Screening

Birth cohort study

Biopanning



Identified multiple targets for vaccine candidates

- **PfGBP130**- blocks invasion
- **PfGARP**- kills intracellular parasites (*Nature*)
- **PfSEA1**- blocks egress (*Science*)

Proprietary drug discovery platform for infectious diseases has yielded promising vaccine and therapeutic candidates for malaria


Activating PfGARP Triggers "Killer Switch"

PfGARP is a protein expressed on the surface of erythrocytes (red blood cells) infected by early-to-late-trophozoite-stage malaria parasites

Anti-PfGARP antibodies **bind to the protein and activate programmed cell death**

Vaccinating individuals with PfGARP (to generate anti-PfGARP antibodies) or directly infusing anti-PfGARP monoclonal antibodies, **would protect them against severe malaria**


PfGARP vaccines **could synergize with other vaccines** that target different phases of the parasite life cycle



Infected red blood cell




Parasite nucleus




PfGARP on surface of red blood cell


Mouse antibodies to PfGARP kill three different strains of *P. falciparum* by 94-99%.




Monoclonal anti-PfGARP kills *P. falciparum*



Recombinant protein immunization of non-human primates with PfGARP



mRNA based immunization of non-human primates with PfGARP



Key takeaways about our vaccine and therapeutic candidates for malaria - and about our infectious disease target discovery platform

Scientifically Compelling

- **Novel targets:** PfGARP and PfSEA-1 are critical for parasite survival
- **Proof of Concept:** 100% killing of malaria parasites in in-vitro assays; >90% killing of malaria parasites in mRNA-based immunization of non-human primates
- **Potentially well-tolerated:** targets have no homology to any human proteins; mRNA vaccine delivery platform is same one used by Pfizer/BioNTech for COVID-19 vaccines

Strong commercial potential

- **Seeks to address major unmet need:** parasites have developed resistance against standard of care drugs; other therapies leave unmet need
- **Seeks to address underserved markets** in public, private and traveler segments

Opportunity for growth into other infectious diseases

- **Our drug target discovery platform** has potential to discover targets against other infectious diseases such as tuberculosis or the next pandemic virus

Executive Summary

Accessing innovations, developing them into high-value, clinical assets, and unleashing their value

Sourcing best-of-breed academic innovations to develop first-in-class biopharma products

- **Advantaged access to university & medical center inventions** - maximizing their economic upside & involvement
- **'Drinking from a fire hose' opportunity pipeline** - continuously fuels Ocean's portfolio growth and diversification
- **Bridging the bench-to-bedside gap *AT SCALE*** - through Ocean's efficient operations and financial strength

Near-term outsized value creation potential from initial mAb, small molecule, and vaccine candidates

- **Addressing multiple, multi-billion \$\$ unmet needs** - in cancer, fibrosis, and infectious disease
- **Based on new, master-switch biological targets & first-in-class candidates** - discovered by our founders
- **De-risked and validated through \$123.9M in non-dilutive grant funding** - past and on-going
- **Clear paths to value inflection points** - high-potential candidates nearing IND submission
- **Market cap is poised to grow** - based on strength of Ocean's portfolio and business vs recent comparable IPOs

Disciplined asset-centric operation ensures optionality to maximize value creation and capture

- **Objective, stage-gated portfolio management** - ensures Ocean's focus is on assets with the highest potential
- **Many shots on goal** - through a variety of product candidates for core & adjacent therapeutic indications
- **Multiple value-capture mechanisms** - spinoffs, partnerships with pharma, in-house market launch
- **Expansive growth pathways** - continual access to more assets from existing and new academic partners



Thank you
